Small intestine cancer accounts for fewer than 3% of gastrointestinal neoplasms despite the small bowel comprising approximately 75% of GI tract length. That rarity, combined with nonspecific symptoms that closely mimic benign disease, produces a consistent pattern of delayed diagnosis: adenocarcinoma averages six to eight months from symptom onset to diagnosis, and small bowel neuroendocrine tumors average 36 months. Four histologically and clinically distinct subtypes — adenocarcinoma, neuroendocrine tumors, GIST, and lymphoma — each require different staging, treatment, and coding approaches. Median survival in patients over 60 is approximately half that of younger adults, underscoring the clinical cost of diagnostic delay in a predominantly older population.
AAVBC's Small Intestine Cancer Quick Reference Guide gives primary care clinicians a structured reference for recognizing and documenting a cancer that is easy to miss and costly to delay. It covers histologic subtype differentiation, anatomic subsite ICD-10 coding, complication documentation, metastatic site coding, and MEAT documentation standards — grounded in current NCCN and ENETS guideline evidence, and built around the clinical vigilance this condition demands.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of small intestine cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Small intestine cancer accounts for fewer than 3% of gastrointestinal neoplasms despite the small bowel comprising approximately 75% of GI tract length. That rarity, combined with nonspecific symptoms that closely mimic benign disease, produces a consistent pattern of delayed diagnosis: adenocarcinoma averages six to eight months from symptom onset to diagnosis, and small bowel neuroendocrine tumors average 36 months. Four histologically and clinically distinct subtypes — adenocarcinoma, neuroendocrine tumors, GIST, and lymphoma — each require different staging, treatment, and coding approaches. Median survival in patients over 60 is approximately half that of younger adults, underscoring the clinical cost of diagnostic delay in a predominantly older population.
AAVBC's Small Intestine Cancer Quick Reference Guide gives primary care clinicians a structured reference for recognizing and documenting a cancer that is easy to miss and costly to delay. It covers histologic subtype differentiation, anatomic subsite ICD-10 coding, complication documentation, metastatic site coding, and MEAT documentation standards — grounded in current NCCN and ENETS guideline evidence, and built around the clinical vigilance this condition demands.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of small intestine cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
